Cancer cytotoxicity
Cytotoxic Mechanisms of Benzimidazole Anthelmintics in Cancer Therapy
Cancer cytotoxicity refers to the ability of a compound or treatment to selectively damage or kill cancer cells while minimizing harm to healthy tissues. In the context of drug repurposing, anti-parasitic anthelmintics—such as fenbendazole, mebendazole, albendazole, and flubendazole—have demonstrated potent, multi-targeted cytotoxic effects across a wide range of human cancer types.
Key Mechanisms Driving Cancer Cytotoxicity
Based on the source materials, these compounds exert cytotoxicity through several distinct biological pathways:
1. Microtubule Disruption & G2/M Cell Cycle Arrest
Benzimidazole anthelmintics bind to the colchicine-binding site on \(\beta\)-tubulin, destabilizing the microtubule network required for cell division.
This prevents normal mitotic spindle formation, arresting cancer cells in the G2/M phase of the cell cycle and leading to mitotic catastrophe and cell death.
2. Induction of Multiple Cell Death Pathways
Apoptosis (Programmed Cell Death): Microtubule damage triggers caspase activation (caspases-3, 7, 8, and 9), cleavage of PARP, mitochondrial cytochrome c release, and modulation of Bcl-2 family proteins (such as Bcl-2 inactivation and Bax upregulation).
Pyroptosis (Inflammatory Cell Death): Fenbendazole induces GSDME-mediated pyroptosis in breast cancer cells by activating the caspase-3/Gasdermin E (GSDME) cascade. Active GSDME forms pores in the cell membrane, leading to cell swelling, membrane rupture, and the release of lactate dehydrogenase (LDH) along with pro-inflammatory cytokines (IL-1\(\beta\) and IL-18).
Ferroptosis & Autophagy: In 5-fluorouracil (5-FU)-resistant colorectal cancer cells, fenbendazole triggers ferroptosis-augmented, p53-independent apoptosis. Other anthelmintics like flubendazole and rafoxanide induce autophagic cell death.
3. Metabolic Starvation & Glucose Uptake Blockade
Cancer cells rely heavily on aerobic glycolysis for energy (the Warburg effect).
Fenbendazole and mebendazole downregulate glucose transporter (GLUT) channels and key glycolytic enzymes such as Hexokinase 2 (HK2). Depriving cancer cells of glucose inhibits ATP production, precipitating metabolic collapse and death within 24 hours.
4. p53 Activation & Proteasomal Stress
Fenbendazole causes post-translational stabilization of the p53 tumor suppressor protein and activation of p21.
It also impairs proteasomal function, creating endoplasmic reticulum (ER) stress and reactive oxygen species (ROS) accumulation that selectively kill tumor cells.
Selectivity and Overcoming Chemoresistance
Selectivity Over Normal Cells: In vitro studies demonstrate that benzimidazoles show high cytotoxic selectivity for cancer cells over healthy cells. For instance, mebendazole inhibits lung and adrenocortical carcinoma lines at micromolar concentrations while leaving normal HUVECs and WI38 fibroblasts unharmed. Similarly, fenbendazole demonstrates up to 14.5-fold selectivity in killing leukemia cells over healthy human bone marrow stem cells.
Overcoming Drug Resistance: Because anthelmintics bind to distinct microtubule sites and evade multidrug-resistance (MDR) efflux pumps, they maintain potent cytotoxicity in cells resistant to standard chemotherapy—including paclitaxel-resistant prostate cancer, 5-FU-resistant colorectal cancer, cisplatin-resistant ovarian and head/neck cancers, and imatinib-resistant chronic myeloid leukemia.
Key Takeaways
High Selectivity: Across almost all studies, benzimidazoles exhibit a high therapeutic index, killing tumor cells at nanomolar-to-low-micromolar concentrations while requiring significantly higher concentrations to affect normal cells (like WI-38 fibroblasts or normal melanocytes).
Efficacy in Chemoresistance: Compounds like mebendazole and fenbendazole consistently demonstrate potency against cells that have developed resistance to paclitaxel, 5-FU, cisplatin, and imatinib.
Mebendazole vs. Fenbendazole Potency: In comparative head-to-head screenings (such as in chemoresistant melanoma or colon cancer), mebendazole generally achieves lower IC50 values (3- to 4-fold more potent) than fenbendazole.